Studies by ours and other groups have shown that a number of EphA2 and EphA3 mutations inactivate Eph receptor canonical signaling by
disrupting ephrin binding or kinase activity, consistent with a role of canonical signaling in tumor suppression.
Not exact matches
«This might mean that strategies to control exosome release could be used to interrupt the
ephrin - Eph signaling pathway and thereby
disrupt tumour growth,» he surmises.
Disrupting either the Wnt or
ephrin pathway throws the growing axons off their targets, shifting the map from side to side.